Sermonix Pharmaceuticals Inc.

Quick facts

Phase 3 pipeline

• Fulvestrant in combination with abemaciclib · Oncology
  Fulvestrant blocks estrogen receptors while abemaciclib inhibits CDK4/6, together suppressing hormone-driven breast cancer cell growth through dual pathway inhibition.
• Lasofoxifene in combination with abemaciclib · Oncology
  Lasofoxifene is a selective estrogen receptor modulator (SERM) that blocks estrogen signaling, combined with abemaciclib, a CDK4/6 inhibitor that prevents cell cycle progression in hormone receptor-positive breast cancer cells.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Sermonix Pharmaceuticals Inc. portfolio CI brief
• Sermonix Pharmaceuticals Inc. pipeline updates RSS